chevron_leftBack
As of 13 June 2026, Intensity Therapeutics, Inc. has a market cap of $12.91M USD, ranking #39882 globally and #5219 in the United States.
It ranks #3553 in the Healthcare sector, and #694 in the Biotechnology industry.
Key Stats
Market Cap
$12.91MUSD
Enterprise Value
$1.41MUSD
Net Income (TTM)
-$11.61MUSD
PB Ratio
1.1
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Lewis Bender
open_in_new
Employees
7
Founded
2012
IPO
30 Jun 2023
Website
intensitytherapeutics.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -1.7% | -2.9% | -16% | -47% | -19% | -68% |
News
Loading...
INTS Analyst Forecasts
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
INTS
ISIN: US45828J2024
Shares Out.:
Shares Outstanding:
2.703M1
Shares Float:
2.58M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
5.08 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Intensity Therapeutics, Inc.
Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NASDAQ: AMGN
|
$182.42B
1M%
|
23.9
|
|
NASDAQ: GILD
|
$159.92B
1M%
|
19.0
|
|
NASDAQ: NTRA
|
$27.6B
214K%
|
-
|
|
NYSE: IQV
|
$26.3B
204K%
|
20.0
|
|
NASDAQ: UTHR
|
$25.03B
194K%
|
20.4
|
|
NASDAQ: MRNA
|
$18.13B
140K%
|
-
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
EBR: ARGX
|
$47.84B
371K%
41.39B EUR
|
39.9
|
|
KRX: 207940
|
$44.84B
347K%
68.19T KRW
|
35.5
|
|
ASX: CSL
|
$42.36B
328K%
60.27B AUD
|
29.3
|
|
SIX: LONN
|
$42.3B
328K%
33.71B CHF
|
37.2
|
|
KRX: 068270
|
$28.11B
218K%
42.76T KRW
|
43.8
|
|
NASDAQ: BNTX
|
$25.69B
199K%
|
-
|
chevron_leftBack